mark88arg
Posted - 2 days ago
$ZURA is safe buying at this level of price ??
NothingToLose1
Posted - 4 days ago
$ZURA hope to see some strong, steady growth this month.
NothingToLose1
Posted - 1 week ago
$ZURA inverted hammer
NothingToLose1
Posted - 1 week ago
$ZURA gains on a deep red day. She wants to climb.
Hereinbama35
Posted - 1 week ago
$ZURA why?
NothingToLose1
Posted - 1 week ago
$ZURA I love a good sale.
NothingToLose1
Posted - 1 week ago
$ZURA gonna be a hell of a year.
CatHerder69
Posted - 2 weeks ago
$ZURA Warrants have been moving. What’s up?
_www_larval_com_
Posted - 2 weeks ago
$ZURA just sunk -4% lower to -12% (~776Kv) a moment ago, follow for more volatility.
Hereinbama35
Posted - 2 weeks ago
$ZURA Why is this dumping?
Stock_Titan
Posted - 2 weeks ago
$ZURA Zura Bio Commences Warrant Exchange Offer and Consent Solicitation
https://www.stocktitan.net/news/ZURA/zura-bio-commences-warrant-exchange-offer-and-consent-j4nx80s7zrx5.html
NothingToLose1
Posted - 2 weeks ago
$ZURA I think this company has strong fundamentals and potential products. Looking forward to seeing how things go over the next few years.
NothingToLose1
Posted - 3 weeks ago
$ZURA just kidding, monday!
NothingToLose1
Posted - 3 weeks ago
$ZURA tomorrow, we ride!
NothingToLose1
Posted - 3 weeks ago
$NKE I'm out, all in on $ZURA . I'd say it's been fun but....
Ulong
Posted - 3 weeks ago
$ZURA 👇🚀👇🚀👇
Ulong
Posted - 3 weeks ago
$ZURA $GLUE "Watching Monte Rosa Therapeutics, Zura Bio; Shares See Volume Amid TipRanks Issues Report Mentioning The Two Stocks"
https://blog.tipranks.com/these-2-strong-buy-penny-stocks-could-jump-at-least-300-says-piper-sandler/
Ulong
Posted - 1 month ago
$AVTX $JASP $ZURA are presenting at the Oppenheimer Novel Targets in Immunology in New York, NY, Panel Discussion: “Novel Immunological Mechanisms for Dermatologic Disorders” on Monday, June 24, 2024, 11:45 a.m. EDT
Ulong
Posted - 1 month ago
$ZURA "Zura Bio to Attend June 2024 Investor Conferences"
Oppenheimer Novel Targets in Immunology Summit. Here, Robert Lisicki, the Chief Executive Officer of Zura Bio, will participate in a panel discussion titled “Novel Immunological Mechanisms for Dermatological Disorders.” Furthermore, he will also conduct one-on-one meetings on Monday, June 24, 2024, in New York, NY. This summit offers a crucial opportunity for Mr. Lisicki to present Zura Bio's strategic vision and innovative therapies targeting dermatological conditions.
Zura Bio is currently advancing three therapeutic assets, all of which have completed Phase 1/1b clinical studies and are ready to enter Phase 2 trials. The company’s portfolio includes tibulizumab (ZB-106), ZB-168, and torudokimab (ZB-880). These assets are being developed to address unmet medical needs in autoimmune and inflammatory diseases, with a focus on conditions such as systemic sclerosis.
(...2...)
TickerDD_com
Posted - 1 month ago
From 5/23/2024, looking back across 21 Month-Ends for ZURA, Percentage Change of Average Monthly Price had More Positives (64%) while Percentage Change of Average Monthly Volume had All Positives (100%) $ZURA #ZURA #ZURAStock #TickerDD https://www.youtube.com/watch?v=MoI2qS0CXJM
SocioCobb
Posted - 1 month ago
$ZURA 👀
SocioCobb
Posted - 1 month ago
$ZURA 👍
SocioCobb
Posted - 1 month ago
$ZURA 👀
briefingcom
Posted - 1 month ago
Gapping up: $ADBE +14.1% $MOLN +11.4% $ZKH +10.9% $BITF +7.8% $ZURA +4.8%
DonCorleone77
Posted - 1 month ago
$ZURA Zura Bio presents data for tibulizumab program at EULAR 2024 Zura Bio shared supportive data from a Phase 1 study evaluating its lead candidate, tibulizumab (ZB-106), for the treatment of Sjogren's syndrome. These data, along with preclinical data supporting further development of tibulizumab in rheumatoid arthritis, were presented at the Annual European Congress of Rheumatology 2024 in Vienna. "Collectively, these data add to early-phase evidence demonstrating that dual-inhibition of both IL-17A and BAFF could be a breakthrough approach for autoimmune and inflammatory diseases in which single-pathway inhibition is the standard of care," stated Robert Lisicki, CEO. "The results in Sjogren's syndrome demonstrate that tibulizumab achieved robust target engagement, nearing maximum serum levels following single, well-tolerated subcutaneous doses at four-week intervals. Further, the preclinical results suggest dual-pathway inhibition may warrant clinical exploration in RA and other autoimmune diseases, adding to the breadth of potential we see with tibulizumab." The randomized, double-blind, placebo-controlled Phase 1 study evaluated four ascending doses of tibulizumab in 25 participants with Sjogren's syndrome. Twenty-one participants in the 12-week study received greater than or equal to1 dose of tibulizumab (30mg Q4W, 100mg Q4W, 300mg Q4W, 300mg Q2W), with four receiving placebo. Treatment with tibulizumab was generally well tolerated in patients with Sjogren's syndrome. Serum levels of total IL-17A and BAFF increased following tibulizumab administration, reflecting target engagement. At doses of 100 mg Q4W and higher, the total IL-17A and BAFF concentrations appeared to plateau, suggesting the targets were engaged nearly to maximum levels. Throughout the study, total B cell counts were dose-dependently reduced in all participants, while administration of tibulizumab was associated with lower levels of Th1 cells. Tibulizumab was also shown to modulate inflammatory mediators, including serum amyloid A, interleukins 5 and 10, as well as basic fibroblast growth factor. These reductions suggest tibulizumab has treatment potential for additional autoimmune conditions.
Stock_Titan
Posted - 1 month ago
$ZURA Zura Bio Presents Data for the Tibulizumab (ZB-106) Program at EULAR 2024
https://www.stocktitan.net/news/ZURA/zura-bio-presents-data-for-the-tibulizumab-zb-106-program-at-eular-9h7rl13l83dg.html
DonCorleone77
Posted - 1 month ago
$ZURA Zura Bio initiated with an Overweight at Cantor Fitzgerald Cantor Fitzgerald initiated coverage of Zura Bio with an Overweight rating and no price target. Zura is a clinical-stage immunology company with a portfolio of in-licensed antibodies that target multiple pathways as single agents, the analyst tells investors in a research note. The firm says that with a "modest" $250M market cap and clinical programs addressing high unmet needs, the shares reflect a much lower probability of success than the biology merits. If any of the Zura pipeline programs succeed, peak sales of over $1B would be achievable, justifying a potential valuation in excess of $3B, Cantor contends.
DonCorleone77
Posted - 1 month ago
$ZURA Zura Bio forms Scientific Advisory Board with leading experts Zura Bio announced the formation of a Scientific Advisory Board with leading experts from rheumatology, dermatology, and immunology. The five distinguished founding members of the SAB are Johann Gudjonsson, M.D, Ph.D., Dinesh Khanna, M.D., M.Sc., Ajay Nirula, M.D., Ph.D., Michael Weinblatt, M.D. and Steven Ziegler, Ph.D. "With the launch of the SAB, we are strengthening our commitment to advancing solutions in translational and clinical science across our portfolio," stated Michael Howell, Ph.D., Chief Scientific Officer and Head of Translational Medicine.
hotcandlestick
Posted - 1 month ago
$ZURA - Found a candlestick pattern on the Wednesday, June 05, 2024 daily chart. https://www.hotcandlestick.com/ZURA
